Skip to content
Combined Shape Created with Sketch.
  • COVID-19
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • More
    • Events
    • Subscribe
    • About
    • Send a Tip
    • Advertising
    • Privacy Policy
  • COVID-19
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • Events
  • About
  • Send a Tip
  • Advertising
  • Privacy Policy

Ad26.COV2-S

02.17.21

J&J Submits Single-Dose COVID-19 Vaccine for EMA Review

Source: FirstWord

02.05.21

J&J Files Single-Dose COVID-19 Vaccine for US Emergency Use

Source: FirstWord

01.29.21

J&J’s Single-Dose COVID-19 Vaccine 66% Effective

Source: FirstWord

01.14.21

Early Study Shows J&J’s One-Dose COVID-19 Vaccine Triggered Antibodies in all Participants

Source: FirstWord

08.21.20

J&J Looking to Enroll 60,000 Participants in Coronavirus Vaccine Trial

Source: FirstWord

08.14.20

EU Wraps Up Exploratory Talks With J&J to Secure Coronavirus Vaccine

Source: FirstWord

06.10.20

Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate

Source: Johnson & Johnson

View more stories

Home

Menu

Share

  • Cataract and Refractive
  • Cornea
  • Glaucoma
  • Healthcare
  • Innovation
  • Optometry
  • Product Approvals
  • Retina
  • Events
  • About
  • Send a Tip
  • Advertising
  • Contact
  • EyewireTV
  • Stocks
  • Privacy Policy
Created with Sketch. Created with Sketch. Created with Sketch. Created with Sketch.
eyewire-news-color bmc-mark Created with Sketch.

© 2021 Bryn Mawr Communications, LLC.

All Rights Reserved.